Press releases

XNK Therapeutics AB today announced that Johan Liwing, CEO, will present the company at the DNB Nordic Healthcare Conference in Oslo, Norway, on December 14 at 10:15am CET.

XNK Therapeutics AB (“XNK”) today announced that Johan Liwing, CEO, will present the company at the at Investival Showcase Meeting in London, on November 13[th]

XNK Therapeutics AB (”XNK”) participates in the SITC meeting, which takes place in San Diego, USA, and will present the latest research relating to the company’s leading natural killer (NK) cell therapies. Two abstracts have been accepted for presentation at the meeting.

XNK Therapeutics AB (“XNK”) today announced that it has applied for and been granted funding by Sweden’s innovation agency Vinnova. The grant consists of SME support through the Competence…

XNK Therapeutics AB today announced that Anna-Karin Maltais, Chief Scientific Officer, will be speaking at the 2[nd] Annual Innate Killer Europe Summit in London on October 18.

XNK Therapeutics AB today announced that two posters, regarding bladder cancer (BC) and acute myeloid leukemia (AML) respectively, was presented at the 20[th] Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September.

XNK Therapeutics AB (“XNK”) today announced that Linda Brick, Head of QA, will be speaking at the 8th CAR-TCR Summit in Boston.

XNK Therapeutics AB (“XNK”) today announced that the company has entered into a research collaboration with the Karolinska University Hospital, Sweden, to evaluate the suitability of the company’s autologous natural killer (NK) cell therapy candidate XNK02 as a novel therapy for treatment of acute myeloid leukemia (AML).

XNK Therapeutics AB today announced that two posters, regarding bladder cancer and Acute Myeloid Leukemia (AML) respectively, will be presented at the 20[th] Meeting of the Society for Natural Immunity (NK2023) in Oslo, Norway, in September.

XNK Therapeutics AB (“XNK”) today announced that the company has entered into an agreement with a US biotechnology company. Under the agreement the parties will perform preclinical evaluation of…

XNK Therapeutics AB today announced that the abstracts Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer and Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment will be presented at the 38[th] Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego in November.

XNK Therapeutics AB today announced that it has been selected as one of three winners of Business Sweden’s Catalyst program 2023. The program identifies Swedish companies having the strongest prerequisites to scale up globally.

XNK Therapeutics today announced the appointment of Hugo Petit as Chief Financial Officer (CFO) and member of the company’s leadership team. Hugo Petit has extensive experience in the life sciences sector and has served as CFO in both public and privately held companies.

XNK Therapeutics today announced that its CEO Johan Liwing will present at ABG Sundal Collier’s Life Science Summit in Stockholm, Sweden, on May 31 at 10:00am CEST.

XNK Therapeutics AB (“XNK”) today announced that the company’s autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global pharma company.

XNK Therapeutics today announced that it has been approved as an EU Tissue Establishment. This certificate allows the company to take control of the complete manufacturing chain, from withdrawal of blood from the patient at the clinic to the delivery of the finished autologous NK-cell based medicinal product.

XNK Therapeutics AB today announced its extensive participation at the 8[th] Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30.

XNK Therapeutics today announced that it has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical Products Agency, which means that the company can produce at scale for its planned clinical studies.

XNK Therapeutics AB’s CEO Johan Liwing will present at Redeye’s Regenerative Medicine/Cell Therapy event on February 22 between 09:00-12:00 CET.

XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Peter Hovstadius as Chief Medical Officer (CMO), effective immediately. Dr. Hovstadius will be a member of the company’s management team. Dr. Johan Aschan who retires from his position as CMO will continue as the company’s Senior Medical Advisor.